At least in some preclinical tumor models, including subcutaneous MC38 CRCs and H22 hepatocellular carcinomas growing in immunocompetent hosts, cisplatin also appears unable to unlock full-blown therapeutic responses to PD-1 blockers, irrespective of relative administration schedule [27, 32], which may reflect the limited ability of cisplatin to elicit ICD in some settings [37]. Here, PDCD1 is linked to neoplasm.